Catalyst

Slingshot members are tracking this event:

New SPINRAZA (nusinersen) Data in Spinal Muscular Atrophy Unveiled at AAN Annual Meeting

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
BIIB

100%

Additional Information

Additional Relevant Details
An additional analysis – which was led by researchers at Columbia University Medical Center with support from Biogen – evaluated a subset of data from CS2 and CS12, two multicenter, open-label clinical trials, to assess the change in participants’ performance during the Six-Minute Walk Test (6MWT) and measures of fatigue. The analysis examined the walking ability and fatigability of ambulatory participants (n=14) ages two to 15 years with SMA Type 2 (n=1) or Type 3 (n=13) at study enrollment. Participants’ baseline median distance walked was 250.5 meters and baseline median fatigue level was 14.8 percent. Following SPINRAZA treatment, their walking distance increased (a median increase of 98 meters) while simultaneously, their fatigue level remained stable or decreased (a median decrease of 3.8 percent) over nearly 3 years.
http://media.biogen....
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 23, 2018
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Spinraza, Nusinersen